Tocotrienol Against the Progression of End Stage Liver Disease

G
Gayle Gordillo, MD

Primary Investigator

Overview

The purpose of this study is to see if oral tocotrienol (TCT) will significantly reduce the rise in Model for End Stage Liver Disease (MELD) score over time in patients with Nonalcoholic Steatohepatits (NASH).

Description

Vitamin E is a generic term for tocotrienols (TCT).  Natural vitamin E, TCT is found in the seed of a number of important cereal grains including wheat, barley and rice.  The United States Food and Drug Administration (FDA) has recently determined that GRAS (Generally Recognized As Safe) status for TCT for inclusion in food products.  The purpose of this study is to see if oral tocotrienol (TCT) will significantly reduce the rise in Model for End Stage Liver Disease (MELD) score over time in patients with Nonalcoholic Steatohepatits (NASH). MELD is used as a measure of mortality risk in patients with end-stage liver disease.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Liver Disease, Nonalcoholic Steatohepatitis (NASH)
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria

ESLD patients with biopsy-diagnosed NASH: :  Liver biopsy within 12 months of screening consistent with NASH cirrhosis (evidenced by F4 fibrosis with or without the presence of steatohepatitis according to the NASH CRN classification, in the opinion of the central reader)
Absence of any other possible cause for liver dysfunction
Able to speak and understand English

Exclusion Criteria

Rapid deterioration of liver function
Hepatocellular carcinoma
Positive HIV/ AIDS, or other chronic immunodeficiency
Concurrent hepatitis infection
Bacterial infection at time of enrollment
Daily use of dedicated vitamin E supplementation within the 12 months prior to study participation
Women who are pregnant, breastfeeding, or plan to become pregnant during course of study participation (36 months)
Other significant comorbidities which limit the subject’s life expectancy to less than 36 months
Concurrent enrollment in another clinical trial
Use of medication known to cause hepatic injury within 3 months from screening/enrollment
History of liver transplantation
Current or history of HCC
HIV infection
Any weight reduction surgery in the preceding 2 years prior to screening or planned surgery during the study
Chronic HCV infection. Subjects cure of HCV infection less than 5 years prior to the screening visit are not eligible
Malignancy within 5 years of screening with the exception of
-Adequately treated carcinoma in situ of the cervix
-Adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer

Updated on 09 Mar 2024. Study ID: 1807361301 (SURG-MPOB-FDA-LIVER)
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center